Detection of perineural invasion in prostate needle biopsies with deep neural networks.
Artificial intelligence
Pathology
Perineural invasion
Prostate cancer
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
26
01
2022
accepted:
10
04
2022
revised:
25
03
2022
pubmed:
23
4
2022
medline:
28
6
2022
entrez:
22
4
2022
Statut:
ppublish
Résumé
The presence of perineural invasion (PNI) by carcinoma in prostate biopsies has been shown to be associated with poor prognosis. The assessment and quantification of PNI are, however, labor intensive. To aid pathologists in this task, we developed an artificial intelligence (AI) algorithm based on deep neural networks. We collected, digitized, and pixel-wise annotated the PNI findings in each of the approximately 80,000 biopsy cores from the 7406 men who underwent biopsy in a screening trial between 2012 and 2014. In total, 485 biopsy cores showed PNI. We also digitized more than 10% (n = 8318) of the PNI negative biopsy cores. Digitized biopsies from a random selection of 80% of the men were used to build the AI algorithm, while 20% were used to evaluate its performance. For detecting PNI in prostate biopsy cores, the AI had an estimated area under the receiver operating characteristics curve of 0.98 (95% CI 0.97-0.99) based on 106 PNI positive cores and 1652 PNI negative cores in the independent test set. For a pre-specified operating point, this translates to sensitivity of 0.87 and specificity of 0.97. The corresponding positive and negative predictive values were 0.67 and 0.99, respectively. The concordance of the AI with pathologists, measured by mean pairwise Cohen's kappa (0.74), was comparable to inter-pathologist concordance (0.68 to 0.75). The proposed algorithm detects PNI in prostate biopsies with acceptable performance. This could aid pathologists by reducing the number of biopsies that need to be assessed for PNI and by highlighting regions of diagnostic interest.
Identifiants
pubmed: 35449363
doi: 10.1007/s00428-022-03326-3
pii: 10.1007/s00428-022-03326-3
pmc: PMC9226086
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-82Subventions
Organisme : Cancerfonden
ID : CAN 2017/210
Organisme : Syöpäsäätiö
ID : 341967, 334782
Informations de copyright
© 2022. The Author(s).
Références
Lancet Oncol. 2020 Feb;21(2):222-232
pubmed: 31926806
Urology. 2013 Feb;81(2):354-7
pubmed: 23374801
Lancet Oncol. 2015 Dec;16(16):1667-76
pubmed: 26563502
Scand J Urol. 2019 Oct;53(5):287-294
pubmed: 31401922
Histopathology. 2020 May;76(6):790-792
pubmed: 32402150
Histopathology. 2020 Aug;77(2):284-292
pubmed: 32285460
Eur Urol. 2018 Aug;74(2):204-210
pubmed: 29331214
Lancet Oncol. 2020 Feb;21(2):233-241
pubmed: 31926805
Pathology. 2018 Apr;50(3):298-304
pubmed: 29448999
Mod Pathol. 2018 Jan;31(S1):S96-109
pubmed: 29297497
IEEE Trans Pattern Anal Mach Intell. 2020 Feb;42(2):318-327
pubmed: 30040631
J Clin Pathol. 2020 Oct;73(10):630-635
pubmed: 32034057
Pathology. 2019 Jan;51(1):11-20
pubmed: 30477882
Virchows Arch. 2021 Jun;478(6):1109-1116
pubmed: 33534005
JAMA Netw Open. 2019 May 3;2(5):e194337
pubmed: 31150073
Hum Pathol. 2001 Aug;32(8):828-33
pubmed: 11521227
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Mayo Clin Proc. 2014 Mar;89(3):308-18
pubmed: 24486077
Proteomics Clin Appl. 2019 Jan;13(1):e1800057
pubmed: 30520559
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724